# ETH Zurich tests electrocatalytic Echo implant to lower blood glucose in mice

- Published: 2026-11-07 01:46 UTC
- Section: Life & Health › Medicine
- Tags: ETH Zurich Echo implant, electrocatalytic glucose implant, diabetes type 2 treatment, Martin Fussenegger, closed-loop glucose control, gluconate conversion
- URL: https://realtech.media/news/rt-b3a543dbfa320791ac5a15ac_eth_zurich_tests/

**Researchers developed an implantable catalyst that converts excess glucose into gluconate using electric current, normalizing blood sugar in mice within an hour.**

![ETH Zurich tests electrocatalytic Echo implant to lower blood glucose in mice](https://realtech.media/media/2026/11/8eba3069400136e4.jpg)
*A1C Ashlee Galloway, Wikimedia Commons, Public domain*

Researchers at ETH Zurich led by Martin Fussenegger have developed an implantable device that lowers blood sugar levels through an electrocatalytic process instead of medications, as reported by lomazoma.com based on a study published in Science. The prototype system, named Echo (Electrocatalytic Closed-Loop Health Optimization), directly converts excess blood glucose into gluconate, which is subsequently excreted by the kidneys through urine [1].

## Catalytic conversion mechanism

The implant contains graphite felt coated with gold structures and nanoscale platinum particles. When an electric current is applied, the surface catalyzes the direct chemical conversion of glucose without requiring living cells or biological enzymes [1]. The system operates on low voltage and does not induce tissue damage from electrical or thermal effects during operation, according to the developers. 

The device integrates with external glucose monitoring sensors, such as those worn on the upper arm, via Bluetooth connectivity managed by a smartphone. When tissue glucose levels exceed a designated threshold, the catalyst activates automatically and shuts off once blood sugar drops back to target levels [1]. In laboratory settings, the team evaluated the technology in five liters of glucose-rich fluid to simulate adult human blood volume.

## In vivo evaluation and technical limits

During in vivo trials on obese mice with type 2 diabetes, the elevated blood glucose levels decreased to normal parameters within one hour after activation [1]. Over a six-week observation period, the treated animals also demonstrated weight loss, while the automated closed-loop control system was tested continuously for twelve days [1].

Despite the positive animal results, the implant is not yet tested on humans and cannot replace underlying insulin deficiencies. Independent experts point out that scaling the device to human blood volumes remains unresolved, potentially requiring larger or multiple implants. Additionally, treated mice showed increased levels of ketone bodies, raising questions about potential risks of ketoacidosis in individuals with severe insulin deficiency. The research team intends to develop the prototype into a medical product.

## Sources

1. [lomazoma.com](https://lomazoma.com/diabetes-implantat-wirkt-schon-nach-einer-stunde-doch-es-gibt-einen-haken)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-b3a543dbfa320791ac5a15ac_eth_zurich_tests/